Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Public ClinicalTrials.gov record NCT02649790. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate cancer (mCRPC), higher risk myelodysplastic syndrome (HRMDS), acute myeloid leukemia (AML) and newly diagnosed intermediate/high-risk MDS. Dose escalation and dose expansion may be included for all parts of the study as determined by ongoing study results.
Study identification
- NCT ID
- NCT02649790
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 277 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2016 (Actual)
- Primary completion
- Aug 31, 2024 (Actual)
- Completion
- Dec 23, 2024 (Actual)
- Last update posted
- Mar 19, 2025
2016 – 2024
United States locations
- U.S. sites
- 26
- U.S. states
- 16
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| David Geffen School of Medicine at UCLA | Los Angeles | California | 90095 | — |
| Oncology Institute of Hope and Innovation | Pasadena | California | 91105 | — |
| Rocky Mountain Regional VA Medical Center | Aurora | Colorado | 80045 | — |
| Sarah Cannon Cancer Center - (Colorado Blood Cancer Institute) | Denver | Colorado | 80218 | — |
| (USO) Rocky Mountain Cancer Centers | Littleton | Colorado | 80120-4413 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Cancer and Hematology Centers of Western Michigan | Grand Rapids | Michigan | 49503 | — |
| Sarah Cannon Cancer Center (HCA Midwest KC) | Kansas City | Missouri | 64132 | — |
| Callahan Cancer Center | North Platte | Nebraska | 69101 | — |
| John Theurer Cancer Center at Hackensack UMC | Hackensack | New Jersey | 07601 | — |
| University of New Mexico | Albuquerque | New Mexico | 87131 | — |
| Weill Cornell Medical College | New York | New York | 10021 | — |
| (USO) Oncology Hematology Care | Cincinnati | Ohio | 45236 | — |
| Ohio State University, The James Cancer Hospital and Solove Research Institute | Columbus | Ohio | 43210 | — |
| University of Pennsylvania Abramson Cancer Center Clinical Research Unit | Philadelphia | Pennsylvania | 19104 | — |
| Baptist Cancer Center | Memphis | Tennessee | 38120 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| (USO) Texas Oncology Austin - Midtown | Austin | Texas | 78705 | — |
| (USO) Texas Oncology (Dallas) | Dallas | Texas | 75246 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| (USO) Texas Oncology (Tyler) | Tyler | Texas | 75702 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| University of Virginia | Charlottesville | Virginia | 22903 | — |
| (USO) Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| University of Washington | Seattle | Washington | 98109 | — |
| (USO) Compass oncology | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02649790, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 19, 2025 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02649790 live on ClinicalTrials.gov.